IDEXX Laboratories (NASDAQ:IDXX) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Posted by Brenda Bartman on Nov 3rd, 2026

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) had its price objective lifted by equities research analysts at Morgan Stanley from $805.00 to $810.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley‘s price target suggests a potential upside of 20.25% from the company’s previous close.

Several other analysts also recently commented on IDXX. JPMorgan Chase & Co. reduced their price objective on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research note on Friday, October 16th. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Leerink Partners dropped their target price on IDEXX Laboratories from $725.00 to $715.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. KeyCorp assumed coverage on IDEXX Laboratories in a research note on Monday, October 12th. They set a “sector weight” rating for the company. Finally, Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Eight investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $728.17.

Get Our Latest Stock Report on IDEXX Laboratories

IDEXX Laboratories Trading Up 0.3%

NASDAQ IDXX traded up $1.94 during trading on Tuesday, hitting $673.58. The stock had a trading volume of 317,733 shares, compared to its average volume of 573,822. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $53.06 billion, a PE ratio of 47.44 and a beta of 1.55. The firm has a 50 day moving average price of $536.56 and a 200 day moving average price of $573.88. IDEXX Laboratories has a twelve month low of $500.61 and a twelve month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its earnings results on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.71 by $0.25. The firm had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.19 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm’s revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the company earned $3.22 earnings per share. As a group, equities research analysts forecast that IDEXX Laboratories will post 14.81 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.79% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of IDXX. J.Safra Asset Management Corp acquired a new stake in shares of IDEXX Laboratories in the second quarter worth $25,000. Elevation Wealth Partners LLC lifted its holdings in shares of IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after acquiring an additional 32 shares in the last quarter. Pension & Wealth Management Advisors Inc. acquired a new position in shares of IDEXX Laboratories during the 3rd quarter valued at $29,000. Arlington Trust Co LLC lifted its holdings in shares of IDEXX Laboratories by 46.3% during the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock valued at $32,000 after acquiring an additional 19 shares in the last quarter. Finally, Bell Investment Advisors Inc boosted its position in IDEXX Laboratories by 45.5% during the 3rd quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock worth $33,000 after purchasing an additional 20 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

More IDEXX Laboratories News

Here are the key news stories impacting IDEXX Laboratories this week:

Positive Sentiment: Q3 earnings and revenue beat estimates. IDEXX reported quarterly EPS of approximately $3.96–$3.98, above the $3.71 consensus, while revenue rose about 10% year over year to $1.21 billion versus expectations of $1.19 billion. Recurring diagnostics revenue to veterinarians increased 11%, highlighting continued demand for the company’s core testing services. IDEXX Laboratories Beats Q3 Earnings and Revenue Estimates
Positive Sentiment: FY 2026 guidance was raised. Management now expects EPS of $14.96–$15.16, above the $14.86 analyst consensus, and revenue of $4.7 billion–$4.8 billion, generally in line with expectations. The higher profit outlook was a major catalyst for the stock’s gains following the report. IDEXX Raises Forecast
Positive Sentiment: Analyst and technical signals remain favorable. Morgan Stanley reiterated its Buy rating and $805 price target, citing strong execution and the raised outlook. Separately, IDXX moved above its 200-day moving average, a technical signal often interpreted as evidence of improving long-term momentum. Buy Reiterated on Strong Execution
Negative Sentiment: Some concerns remain about underlying demand and margins. The improved profit forecast does not appear to be driven by stronger veterinary visits, and commentary indicated that the margin outlook has softened. Investors may therefore watch whether diagnostics growth can continue to offset weaker clinic traffic and sustain the elevated valuation.

IDEXX Laboratories Company Profile

(Get Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.